Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.3c00241
Abstract: Galectin-3 binding protein (Gal-3BP) is a glycoprotein that is overexpressed and secreted by several cancers and has been implicated as a marker of both tumor progression and poor prognosis in melanoma, non-small cell lung cancer,… read more here.
Keywords: dfo; 1959 sss; 89zr dfo; gal 3bp ... See more keywords
Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
Sign Up to like & getrecommendations! Published in 2018 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.8b00392
Abstract: Our aim was to synthesize 89Zr-labeled trastuzumab-emtansine (89Zr-DFO-T-DM1) to probe the delivery of trastuzumab-emtansine (T-DM1) to HER2-positive breast cancer (BC) by positron emission tomography (PET). We further aimed to compare the tumor and normal tissue… read more here.
Keywords: 89zr dfo; dm1; trastuzumab; dfo dm1 ... See more keywords
Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0223814
Abstract: Introduction Chimeric antigen receptor (CAR) T-cells have been recently developed and are producing impressive outcomes in patients with hematologic malignancies. However, there is no standardized method for cell trafficking and in vivo CAR T-cell monitoring.… read more here.
Keywords: 89zr dfo; car cell; car cells; cell ... See more keywords
Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.870110
Abstract: The immune cytokine interleukin-12 (IL-12) is involved in cancer initiation and progression, autoimmunity, as well as graft versus host disease. The ability to monitor IL-12 via imaging may provide insight into various immune processes, including… read more here.
Keywords: tracer; 89zr dfo; adv csf; mice ... See more keywords
Therapeutic Response Monitoring with 89Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14071338
Abstract: Immuno-positron emission tomography (PET) has great potential to evaluate the target expression level and therapeutic response for targeted cancer therapy. Immuno-PET imaging with pertuzumab, due to specific recognition in different binding sites of HER2, could… read more here.
Keywords: dfo pertuzumab; therapeutic response; her2; 89zr dfo ... See more keywords
Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14102114
Abstract: 89Zr represents a highly favorable positron emitter for application in immuno-PET (Positron Emission Tomography) imaging. Clinically, the 89Zr4+ ion is introduced into antibodies by complexation with desferrioxamine B. However, producing complexes of limited kinetic inertness.… read more here.
Keywords: 89zr dfo; dfo cetuximab; dfo; 89zr hopo ... See more keywords
Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14122824
Abstract: Antibodies that recognize cancer biomarkers, such as MUC16, can be used as vehicles to deliver contrast agents (imaging) or cytotoxic payloads (therapy) to the site of tumors. MUC16 is overexpressed in 80% of epithelial ovarian… read more here.
Keywords: fully human; dfo; m16ab; 89zr dfo ... See more keywords
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
Sign Up to like & getrecommendations! Published in 2019 at "Theranostics"
DOI: 10.7150/thno.37513
Abstract: Predicting the outcome of immunotherapy is essential for efficient treatment. The recent clinical success of immunotherapy is increasingly changing the paradigm of cancer treatment. Accordingly, the development of immune-based agents is accelerating and the number… read more here.
Keywords: dfo; 89zr dfo; response; cd8a ... See more keywords